Back

Beneficial effect of landiolol on adiponectin and high-molecular weight adiponectin level in patients with stable coronary artery disease performed percutaneous coronary intervention

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 4 - Arrhythmia and cardio protection pharmacotherapy Beta-Blockers ESC Premium Access ESC Congress 2018

About the speaker

Photo
Assistant Professor Masayoshi Kiyokuni

Saiseikai Yokohama City Southern Hospital, Yokohama (Japan)

5 More presentations in this session

Presentation thumbnail
Proarrhythmic pharmacotherapy and out-of-hospital cardiac arrest - A nationwide Danish study
Mr S. Kjeldsen (Gentofte, DK)
Abstract
Presentation thumbnail
Ivabradine is not associated with higher risk of new onset atrial fibrillation among patients with cardiac resynchronization therapy
Doctor J. Milner (Santa Maria da Feira, PT)
Abstract
Presentation thumbnail
Hysteresis between pharmacokinetics and changes in QRS complex duration following flecainide administered via oral inhalation or IV infusion
Ms P. Madhavapeddi (Newark, US)
Abstract Slides
Presentation thumbnail
SK channel inhibition did not increase short-term variability of the QT intervals in atrial tachypaced pigs with left ventricular dysfunction in contrast to the positive control dofetilide
Miss C. Citerni (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
AMPK/PGC1 activation by melatonin attenuates acute doxorubicin cardiotoxicity
Doctor D. Liu (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Poster Session 4 - Arrhythmia and cardio protection pharmacotherapy

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Webinar
Are beta-blockers still indicated after myocardial infarction?
thumbnail
Congress Presentation
Impact of beta-blocker therapy in patients with preserved left ventricular ejection fraction after ST-segment elevation myocardial infarction
thumbnail
Congress Presentation
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources